Diffuse Hepatic Disease and Fatty Infiltration (Table 9.4)

Hepatic Vein Anatomy (context snippet)

  • Accessory hepatic veins are common; the most common variant drains the superoanterior segment of the right lobe and may empty into the middle hepatic vein or join the right hepatic vein.

Diffuse Hepatic Disease

  • Definition: disease that affects hepatocytes and interferes with liver function; hepatocytes are parenchymal liver cells that perform all liver functions.
  • Measurement: diffuse disease is assessed via liver function tests (LFTs).
  • Biochemical patterns:
    • Hepatocellular injury/necrosis: elevated hepatic enzymes (AST, ALT).
    • Cholestasis (impaired bile flow anywhere in biliary system from liver to duodenum): increased alkaline phosphatase (ALP) and direct bilirubin.
    • Impaired protein synthesis (advanced disease): elevated serum bilirubin with decreased serum albumin and reduced clotting factors.
  • Subcategories of diffuse parenchymal disease (examples):
    • Fatty infiltration (fatty liver)
    • Acute hepatitis
    • Chronic hepatitis
    • Early alcoholic liver disease
    • Acute cirrhosis
    • Chronic cirrhosis
  • Reference: Table 9.4 (clinical findings, sonographic findings, and differential considerations for diffuse hepatic disease).

Fatty Infiltration

  • Definition: an acquired, reversible disorder of metabolism characterized by intracellular accumulation of triglycerides within hepatocytes; increased lipid content in hepatocytes.
  • Significance: usually benign and potentially reversible with correction of the underlying cause; can reflect major liver injury or systemic metabolic disturbance.
  • Pathophysiology: excessive or impaired metabolism of fat leading to intracellular triglyceride buildup.
  • Clinical implications: may be asymptomatic or present with variable liver function tests; reversible if underlying cause is addressed.
  • Sonographic findings (diffuse):
    • Increased echogenicity of the liver on ultrasound.
    • Increased attenuation of the ultrasound beam.
    • May show brightness of portal vein borders.
  • Laboratory findings (diffuse):
    • Clinical findings range from normal to elevated hepatic enzymes; pattern can be non-specific.
    • Direct bilirubin and alkaline phosphatase (ALP) may be variably elevated depending on associated processes.
  • Differential considerations ( Table 9.4 ):
    • Hepatitis
    • Cirrhosis
    • Acute hepatitis
  • Notes on interpretation:
    • Fatty liver typically shows increased echogenicity and attenuation on ultrasound; however, clinical context and laboratory data are essential to differentiate from other diffuse diseases.

Table 9.4 Liver Findings: Diffuse Disease (summary interpretations)

  • Fatty Infiltration

    • Clinical findings: Normal to elevated hepatic enzymes (AST/ALT may be normal or up).
    • Laboratory findings: ↑ alkaline phosphatase (ALP); ↑ direct bilirubin; may reflect coexisting cholestasis or bilirubin handling abnormalities.
    • Sonographic findings: ↑ echogenicity; ↑ attenuation; bright portal triad borders; hepatomegaly may be present.
    • Differential considerations: Hepatitis, Cirrhosis, Acute Hepatitis.

  • Hepatitis (acute and chronic)

    • Clinical findings: ↑ AST and/or ALT (typical), ↑ bilirubin; leukopenia can be seen.
    • Lab patterns: acute hepatitis shows ↑ AST/ALT and bilirubin; chronic hepatitis shows persistent elevation of AST/ALT with bilirubin changes and leukopenia.
    • Sonographic findings: hepatomegaly; may be patchy or inhomogeneous; focal sparing possible; visualization of borders may be impaired with increased attenuation.
    • Additional notes: hepatocellular pattern rather than purely cholestatic.

  • Cirrhosis (acute vs chronic)

    • Clinical findings: ↑ ALP; ↑ direct bilirubin; ↑ AST/ALT; leukopenia; hepatomegaly early but liver often becomes shrunken with chronic disease; nodularity develops.
    • Sonographic findings: coarse parenchyma with nodularity; decreased vascular markings; signs of portal hypertension (splenomegaly, varices may be inferred); ascites possible; in advanced chronic cirrhosis liver commonly shrinks and nodularity persists.
    • Notable features: impaired visualization of portal/hepatic borders due to attenuation in some settings; fibrosis may contribute to soft shadowing.

  • Other diffuse/hepatic metabolic or storage disorders listed in Table 9.4 (examples)

    • Glycogen Storage Disease: disturbance of acid-base balance.
    • Hemochromatosis: iron overload; may present with hepatosplenomegaly and ascites.
    • Von Gierke disease (Glycogen storage disease type I): round, homogeneous nodules/regions; ↑ echogenicity throughout liver.
    • Focal nodular hyperplasia and other incidental lesions may be listed alongside fatty liver or cirrhosis as differential considerations in imaging.

Key takeaways and connections

  • Distinguishing features on labs:
    • Hepatocellular injury pattern: ↑ AST/ALT, possibly with ↑ bilirubin; leukopenia may occur in chronic inflammatory states.
    • Cholestatic pattern: ↑ ALP and direct bilirubin.
    • Protein synthesis impairment: hypoalbuminemia and prolonged clotting times may occur in advanced disease.
  • Imaging cues on ultrasound:
    • Fatty Infiltration: brighter liver parenchyma (↑ echogenicity) and increased attenuation.
    • Hepatitis: hepatomegaly, variable echogenicity, possible patchy/inhomogeneous texture.
    • Cirrhosis: coarse, nodular parenchyma, decreased vascular markings, signs of portal hypertension, possible ascites.
  • Practical implications: imaging helps differentiate diffuse parenchymal diseases in the context of lab data; however, overlap exists and clinical correlation is essential.
  • Ethical/philosophical/practical considerations:
    • Early detection of diffuse liver disease can influence lifestyle interventions and treatment planning.
    • Balancing noninvasive imaging with need for biopsy in uncertain cases requires patient-centered discussion and consideration of risks.
  • Formulas and notation used in the notes:
    • Elevation patterns are denoted with arrows in clinical texts, e.g., AST
      ightarrow \uparrow, ALT→↑ALT \rightarrow \uparrow, ALP→↑ALP \rightarrow \uparrow, Direct bilirubin→↑Direct\ bilirubin \rightarrow \uparrow when cholestasis is present.